Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2016, Article ID 1821596, 7 pages
http://dx.doi.org/10.1155/2016/1821596
Research Article

Effects of Ramipril and Telmisartan on Plasma Concentrations of Low Molecular Weight and Protein Thiols and Carotid Intima Media Thickness in Patients with Chronic Kidney Disease

1Department of Biomedical Sciences, University of Sassari, 07100 Sassari, Italy
2Department of Clinical Pharmacology, School of Medicine, Flinders University, Bedford Park, SA 5042, Australia
3Department of Surgical, Microsurgical and Medical Sciences, University of Sassari, 07100 Sassari, Italy

Received 18 May 2016; Revised 28 June 2016; Accepted 29 June 2016

Academic Editor: Manfredi Rizzo

Copyright © 2016 Angelo Zinellu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Hypertension, a common feature in chronic kidney disease (CKD), is an independent risk factor for CKD progression and cardiovascular disease. Although inhibitors of the renin-angiotensin system (RAS) exert salutary effects on blood pressure control and proteinuria in CKD patients, their activity towards traditional and novel oxidative markers is largely unknown. We studied the effects of 6-month treatment with telmisartan versus a combination of telmisartan and ramipril on plasma concentrations of low molecular mass (LMW, including homocysteine and cysteine) and protein thiols (PSH) plasma concentration and their relationships with carotid intima media thickness (IMT), in 24 hypertensive CKD patients (age years, 8 females and 16 males). Pretreatment PSH concentrations were independently associated with IMT (, ). Neither treatment affected plasma LMW thiols, in both reduced and total form. By contrast, both treatments increased PSH plasma concentrations and reduced IMT, although significant differences were only observed in the combined treatment group. Our results suggest that the beneficial effects of combined RAS inhibitor treatment on IMT in hypertensive CKD patients may be mediated by a reduction of oxidative stress markers, particularly PSH.